Ovarian Cancer Clinical Trials in Salt Lake City

Showing 181-200 of 208 trials

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00346385

RATIONALE: Monoclonal antibodies, such as BB-10901, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed or refractory solid tumors.

Ovarian CancerMerkel Cell CarcinomaSCLC

ImmunoGen, Inc.97 participantsStarted Mar 2002

San Francisco, California, United States • Las Vegas, Nevada, United States • Columbus, Ohio, United States +6 more locations

TERMINATEDPhase 2362 miles

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

NCT00003386

RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.

Ovarian Cancer

Gynecologic Oncology GroupStarted Jul 1999

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +57 more locations

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Ovarian Cancer Trials in Other Cities

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Quality of Life in Survivors of Gynecologic Cancer

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk

Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin

Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Other Conditions in Salt Lake City